These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 31347764

  • 1. Bevacizumab in treating the cystic components of pediatric low-grade gliomas: A report of four patients.
    Levenbaum E, Ellika S, Korones DN.
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27917. PubMed ID: 31347764
    [Abstract] [Full Text] [Related]

  • 2. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 3. Bevacizumab as salvage therapy for progressive brain stem gliomas.
    Reithmeier T, Lopez WO, Spehl TS, Nguyen T, Mader I, Nikkhah G, Pinsker MO.
    Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
    [Abstract] [Full Text] [Related]

  • 4. Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab.
    Hsu CH, Lober RM, Li MD, Partap S, Murphy PA, Barnes PD, Fisher PG, Yeom KW.
    J Neurooncol; 2015 May; 122(3):491-6. PubMed ID: 25758812
    [Abstract] [Full Text] [Related]

  • 5. Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.
    Foster KA, Ares WJ, Pollack IF, Jakacki RI.
    Pediatr Blood Cancer; 2015 Feb; 62(2):240-245. PubMed ID: 25382690
    [Abstract] [Full Text] [Related]

  • 6. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
    Gnekow AK, Kortmann RD, Pietsch T, Emser A.
    Klin Padiatr; 2004 Feb; 216(6):331-42. PubMed ID: 15565548
    [Abstract] [Full Text] [Related]

  • 7. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B.
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [Abstract] [Full Text] [Related]

  • 8. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
    Jaspan T, Morgan PS, Warmuth-Metz M, Sanchez Aliaga E, Warren D, Calmon R, Grill J, Hargrave D, Garcia J, Zahlmann G.
    AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
    [Abstract] [Full Text] [Related]

  • 9. Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: three case studies and a review of the literature.
    Hassall TE, Mitchell AE, Ashley DM.
    Neuro Oncol; 2001 Oct; 3(4):251-7. PubMed ID: 11584895
    [No Abstract] [Full Text] [Related]

  • 10. Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.
    Zhukova N, Rajagopal R, Lam A, Coleman L, Shipman P, Walwyn T, Williams M, Sullivan M, Campbell M, Bhatia K, Gottardo NG, Hansford JR.
    Cancer Med; 2019 Jan; 8(1):40-50. PubMed ID: 30569607
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [Abstract] [Full Text] [Related]

  • 12. Lower-grade gliomas: the wrong target for bevacizumab.
    Schiff D, de Groot JF.
    Neuro Oncol; 2018 Nov 12; 20(12):1559-1560. PubMed ID: 30418659
    [No Abstract] [Full Text] [Related]

  • 13. Bevacizumab in the Treatment of Refractory Brain Edema in High-grade Glioma.
    Alsahlawi AK, Michaud-Couture C, Lachance A, Bergeron-Gravel S, Létourneau M, Bourget C, Gould PV, Giannakouros P, Nakada EM, Faury D, Crevier L, Bouffet É, Jabado N, Larouche V, Renzi S.
    J Pediatr Hematol Oncol; 2024 Jan 01; 46(1):e87-e90. PubMed ID: 38032194
    [Abstract] [Full Text] [Related]

  • 14. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
    McDonald CR, Delfanti RL, Krishnan AP, Leyden KM, Hattangadi-Gluth JA, Seibert TM, Karunamuni R, Elbe P, Kuperman JM, Bartsch H, Piccioni DE, White NS, Dale AM, Farid N.
    Neuro Oncol; 2016 Nov 01; 18(11):1579-1590. PubMed ID: 27106406
    [Abstract] [Full Text] [Related]

  • 15. First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.
    O'Connell D, Shen V, Loudon W, Bota DA.
    CNS Oncol; 2017 Jan 01; 6(1):11-18. PubMed ID: 27918194
    [Abstract] [Full Text] [Related]

  • 16. Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
    Koukourakis GV.
    Recent Pat Inflamm Allergy Drug Discov; 2015 Jan 01; 9(2):136-43. PubMed ID: 26256461
    [Abstract] [Full Text] [Related]

  • 17. Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome. Experience in a single institution.
    Sandri A, Sardi N, Genitori L, Giordano F, Peretta P, Basso ME, Bertin D, Mastrodicasa L, Todisco L, Mussa F, Forni M, Ricardi U, Cordero di Montezemolo L, Madon E.
    Childs Nerv Syst; 2006 Sep 01; 22(9):1127-35. PubMed ID: 16568342
    [Abstract] [Full Text] [Related]

  • 18. MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives.
    Tovar-Spinoza Z, Choi H.
    Childs Nerv Syst; 2016 Oct 01; 32(10):1947-56. PubMed ID: 27659837
    [Abstract] [Full Text] [Related]

  • 19. Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
    Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.
    J Pediatr Hematol Oncol; 2015 Aug 01; 37(6):e341-6. PubMed ID: 26056795
    [Abstract] [Full Text] [Related]

  • 20. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G.
    J Nucl Med; 2011 Jun 01; 52(6):856-64. PubMed ID: 21622893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.